MDxHealth « Terug naar discussie overzicht

quote:

SJURVM schreef op 28 mei 2017 21:19:

I was comparing the graph between MDXH and Biomerieux. Both followed each other relatively closely but since the 4 months results a massive gap has appeared.

It seems that the purchases from existing shareholders were necessary to shore up the price. The battle is at €5.02 or thereabouts. If this breaks down I see us going back to €4.40/€4.50.

The Taglich brothers report is interesting. How muc do you value MDXh with accumulated tax losses of $165m and $35m in cash? What is in effect the value of Confirmmdx, Select and Assure?

Just a few thoughts after coming back from holidays.

quote:

fly like an eagle schreef op 29 mei 2017 09:11:

dank voor verslagen bava en interpretaties unrecognized revenues en bijkopen Mariens et al. Ik ben van mening dat geheel mij steunt dat ik er weer wat had terug gekocht en nog wat probeer bij te kopen. ok happy draagt hieraan bij; als je zo veel energie stopt in een forum van een eenbedrijf je geen aandelen in hebt, moet je wel een belang hebben om dit te doen.

quote:

fly like an eagle schreef op 29 mei 2017 09:11:

dank voor verslagen bava en interpretaties unrecognized revenues en bijkopen Mariens et al. Ik ben van mening dat geheel mij steunt dat ik er weer wat had terug gekocht en nog wat probeer bij te kopen. ok happy draagt hieraan bij; als je zo veel energie stopt in een forum van een eenbedrijf je geen aandelen in hebt, moet je wel een belang hebben om dit te doen.

quote:

DWB Happy schreef op 29 mei 2017 09:19:

[...]

Er bestaan dus ook nog mensen die het goed bedoelen zonder een dubbele agenda.

Verder snap ik totaal niet dat sommige mensen het hier alsmaar positief proberen uit te leggen, voor die groep moet je nu juist oppassen.

Sommige mensen willen blijkbaar toch graag genaaid worden....

Succes allen

quote:

BassieNL schreef op 29 mei 2017 09:38:

[...]
of het zijn 'pushers' die betaald worden om positief over het aandeel te schrijven.

Net zoals analisten die betaald krijgen om mooie rapportjes te publiceren.

quote:

DWB Happy schreef op 29 mei 2017 09:53:

[...]

... dat het grote geld juist de koers hoog wil houden.

quote:

kootpenne schreef op 29 mei 2017 03:42:

[...]
Welcome back, Sjurvm, hope you had wonderful holidays.

I don't know why you would compare MDXH and Biomerieux?
Nevertheless, i took the time to see at BIM's First-Quarter 2017 Business Review:

SALES

Consolidated sales rose to €568 million for the first three months of 2017,
up from €489 million in the same period one year earlier. This represents
growth of 16.3% as reported, including a positive currency effect of around
€13 million. Organic growth (at constant exchange rates and scope of
consolidation) represented 13.7% year-on-year, helped by one extra billing day
compared with first-quarter 2016. FilmArray(®) accounted for around half of
the increase, driven by a stronger and longer flu season than in the
prior-year period.

Furthermore they analyse sales by region and by application.
This is the kind of transparent communication I expect to see from a company as a shareholder.

quote:

SJURVM schreef op 29 mei 2017 10:47:

[...]

They are also in the business of biomarkers for prostate cancer...

www.biomerieux.co.uk/biomerieux-devel...

www.ncbi.nlm.nih.gov/pubmed/24954692

quote:

Onderbouwer schreef op 29 mei 2017 11:05:

[...]

Dont worry. MDX is the best in class and rhe cheapest. The worst case scenario is that the concurrents get products of the same quality and price.

But even than, mdx already have the contracts and codes.

quote:

SJURVM schreef op 29 mei 2017 10:47:

[...]

They are also in the business of biomarkers for prostate cancer...

www.biomerieux.co.uk/biomerieux-devel...

www.ncbi.nlm.nih.gov/pubmed/24954692

quote:

Onderbouwer schreef op 29 mei 2017 11:59:

[...]

If you can find 1 test with the same or better quality and with the same or lower price than mdx tests than start worry.

As long you cant find any there is zero worries.

quote:

SJURVM schreef op 29 mei 2017 12:58:

[...]

The original question from Kootpenne was "why was I looking at Biomerieux?"
The answer is that they are the competition. It is a much larger and more diversified company than MDXH.
Who knows maybe they might look at MDXH for their existing and other in the making biomarkers... :)

quote:

SJURVM schreef op 29 mei 2017 13:22:

I will express my concerns with MDXH at the moment:

Slowdown in sales as per 4 month business update. Even though it was taken up by more urologists and covered by insurance companies.
Increase in number of personnel to "collect" the unrecognized revenue. Is this becoming a real problem?
Delay in launching Assuremdx (problem with the product or lack of cash? hence the deal with Exact?)
Suddenly the VA contract becomes extremely important. Why is that and what if it does not deliver?
No new insurance contracts signed in the USA because everyone is waiting for the introduction of 2018 CPT code? What happens in the last few months of 2017

Taglich Brothers used "publicly" available information to write their report in the past. Now they have "reliable sources". In their report the eps improves by $0.04 to -$0.20 by 2018. extrapolating this means it will take 5 years to break-even. Of course it is but one ratio. If there are new capital raising issue and or the sales go up even faster and or the costs go down it might be getting to break-even more quickly.

So, there you have it.

I am still looking forward to the €6.50 by year-end though :)

quote:

kootpenne schreef op 29 mei 2017 14:06:

[...]
I share your concerns but moreover I have a bigger concern. I believe that they will achieve their goal of reaching a growth of 55-75% simply by converting unrecognised revs to turnover. We will not be able to determine organic growth though.
Q3 2016 results excelled, immediately followed by a capital increase. I believe history will repeat itself in 2017.

Again, i hope i am wrong..